Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bahcall

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
Molecular Cancer Therapeutics|February 4, 2021
ERK Inhibitor LY3214996-Based Treatment Strategies for <i>RAS</i>-Driven Lung CancerJens Köhler, Yutong Zhao, Jiaqi Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non-Small Cell Lung CancerElena Ivanova, Mari Kuraguchi, Man Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLCSeshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLCGonzalo Recondo, Magda Bahcall, Liam F Spurr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2018
Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung CancerMagda Bahcall, Mark M Awad, Lynette M Sholl, et al.
Nature Cancer|April 15, 2022
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancerCiric To, Tyler S Beyett, Jaebong Jang, et al.
Nature|December 20, 2003
A gravitationally lensed quasar with quadruple images separated by 14.62 arcsecondsNaohisa Inada, Masamune Oguri, Bartosz Pindor, et al.
Cancer Discovery|April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET InhibitorsFederica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Science Translational Medicine|September 13, 2021
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i>-mutant lung cancerPınar Özden Eser, Raymond M Paranal, Jieun Son, et al.
Cancer Cell|January 15, 2020
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic PathwayKari J Kurppa, Yao Liu, Ciric To, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Molecular Cancer Therapeutics|February 4, 2021
ERK Inhibitor LY3214996-Based Treatment Strategies for <i>RAS</i>-Driven Lung CancerJens Köhler, Yutong Zhao, Jiaqi Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non-Small Cell Lung CancerElena Ivanova, Mari Kuraguchi, Man Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLCSeshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLCGonzalo Recondo, Magda Bahcall, Liam F Spurr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2018
Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung CancerMagda Bahcall, Mark M Awad, Lynette M Sholl, et al.
Nature Cancer|April 15, 2022
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancerCiric To, Tyler S Beyett, Jaebong Jang, et al.
Nature|December 20, 2003
A gravitationally lensed quasar with quadruple images separated by 14.62 arcsecondsNaohisa Inada, Masamune Oguri, Bartosz Pindor, et al.
Cancer Discovery|April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET InhibitorsFederica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Science Translational Medicine|September 13, 2021
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i>-mutant lung cancerPınar Özden Eser, Raymond M Paranal, Jieun Son, et al.
Cancer Cell|January 15, 2020
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic PathwayKari J Kurppa, Yao Liu, Ciric To, et al.
Pageof 14